Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.

Wesana Health reports positive feedback from FDA on pre-IND meeting regarding development of SANA -013 and is anticipating commencing a clinical trial in Q4 2022.

Numinus announces that its Numinus Bioscience research lab has been approved for a Containment Level 2 (CL2) license from Health Canada.

Red Light Holland applauds the decision of Washington State’s government to provide $200,000 in funding for psychedelics research.

Incannex reports a strong clinical response in its trial of a cannabinoid combination product IHL-42X for sleep apnea.

Small Pharma announces two more planned clinical trials for 2022 from its pipeline of DMT-based drug candidates.

UK-based Albert Labs announces its official trading date on Canada’s CSE exchange. The Company will commence trading Thursday, March 11th under the symbol “ABRT”

With a mental health catastrophe in the United States spiraling out of control, the Biden “plan” is just more of what has failed.

Novamind announces it will conduct a Phase II clinical trial for the sponsor, Usona Institute, on a psilocybin-based therapy for MDD.

Apex has secured its Veteran patient base, clinical trial location and Qualified Investigator for its phase 2a program expected to launch as early as Q2/Q3 2022.